<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791842</url>
  </required_header>
  <id_info>
    <org_study_id>2010.648</org_study_id>
    <secondary_id>2010-024282-41</secondary_id>
    <nct_id>NCT01791842</nct_id>
  </id_info>
  <brief_title>TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE</brief_title>
  <acronym>TOCIDYS</acronym>
  <official_title>TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small
      proportion of patients fail to respond adequately. Mutated bone cells produce large amounts
      of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may
      be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a
      placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can
      reduce bone resorption in those patients with fibrous dysplasia who have already received
      bisphosphonates.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum CTX (type 1 collagen C-terminal breakdown product)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone pain</measure>
    <time_frame>6 months</time_frame>
    <description>visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ICTP (Carboxyterminal Telopeptide of Type I Collagen)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone alkaline phosphatase</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiographs of mostly affected area</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Biological safety</measure>
    <time_frame>12 months</time_frame>
    <description>serum creatinine level, red blood cells, white blood cells, platelets, ASAT (Aspartate Amino Transferase), ALAT (Alanine Amino Transferase), CRP (C Reactive Protein) : each month cholesterol, triglycerides : before experimental treatment administration and at 8 weeks</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Fibrous Dysplasia of Bone</condition>
  <arm_group>
    <arm_group_label>Tocilizumab first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>8 mg/kg/month</description>
    <arm_group_label>Tocilizumab first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tocilizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Tocilizumab first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fibrous dysplasia of bone

          -  previously treated with IV bisphosphonates

          -  persistent bone pain and increased bone remodeling

        Exclusion Criteria:

          -  Chronic renal failure

          -  serious infectious diseases

          -  liver enzymes abnormality

          -  pregnancy

          -  dyslipidemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roland CHAPURLAT, Professor</last_name>
    <phone>+33472117481</phone>
    <email>roland.chapurlat@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah GENSBURGER, Dr</last_name>
    <phone>+33472119702</phone>
    <email>deborah.gensburger@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - service de rhumatologie</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Chapurlat, Professor</last_name>
      <phone>+33472117481</phone>
    </contact>
    <investigator>
      <last_name>Roland CHAPURLAT, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah GENSBURGER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière - service de rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe ORCEL, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Philippe ORCEL, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.dysplasie-fibreuse-des-os.info</url>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrous dysplasia of bone</keyword>
  <keyword>tocilizumab</keyword>
  <keyword>McCune-Albright syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

